

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
PATENT EXAMINING OPERATION

First Named Inventor: Peter William SURMAN

Serial No: 10/561,930

Group Art Unit: 1618

Filed: 05-23-2006

Examiner: VU, JAKE MINH

Att. Docket No.: D2026/20001

Confirmation No.: 3207

For: STABLE CLOZAPINE SUSPENSION FORMULATION

**ELECTION**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INTRODUCTORY COMMENTS**

In response to the Office Action dated December 1, 2009, setting forth a requirement for restriction, and in accordance with the provisions of 37 CFR 1.111 and 1.143, Applicants provisionally elect **with traverse** Group I, claims 27-38 drawn to a composition comprising clozapine suspension.

Remarks/Arguments begin on page 2 of this paper.

**CERTIFICATE OF MAILING/TRANSMISSION PURSUANT TO 37 CFR 1.8**

I hereby certify that this correspondence and any attachments referenced therein is/are being mailed/transmitted to the USPTO by: (A) first class U.S. mail with sufficient postage (37 CFR § 1.1(a)); (B) facsimile (37 CFR § 1.6 (d)); or (C) EFS-Web (37 CFR § 1.6(a)(4)) on the date shown below.

Date: 12/7/2009

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Joseph F. Murphy